Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

SML2586

Sigma-Aldrich

(S)-C33

≥98% (HPLC)

Synonym(s):

6-[[(1S)-1-(4-Chlorophenyl)ethyl]amino]-1-cyclopentyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, C33(S)

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
$91.86
25 MG
$310.00

$91.86

List Price$96.90Save 5%

In StockDetails

Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
$91.86
25 MG
$310.00

About This Item

Empirical Formula (Hill Notation):
C18H20ClN5O
CAS Number:
2066488-39-7
Molecular Weight:
357.84
MDL number:
MFCD31579858
UNSPSC Code:
12352200
NACRES:
NA.77

$91.86

List Price$96.90Save 5%

In StockDetails

Request a Bulk Order

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C1C2=C(N=C(N1)N[C@H](C3=CC=C(C=C3)Cl)C)N(C4CCCC4)N=C2

Biochem/physiol Actions

(S)-C33 [C33(S)] is a potent and selective phosphodiesterase-9A (PDE9A) inhibitor that upregulates cGMP signaling. (S)-C33 protects against cardiac hypertrophy and postpones the transition to heart failure in rat models.
potent and selective phosphodiesterase-9A (PDE9A) inhibitor

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Manna Huang et al.
Molecular pharmacology, 88(5), 836-845 (2015-09-01)
Phosphodiesterase-9 (PDE9) inhibitors have been studied as potential therapeutics for treatment of central nervous system diseases and diabetes. Here, we report the discovery of a new category of PDE9 inhibitors by rational design on the basis of the crystal structures.
Pan-Xia Wang et al.
Acta pharmacologica Sinica, 38(9), 1257-1268 (2017-06-27)
Phosphodiesterase-9A (PDE9A) expression is upregulated during cardiac hypertrophy and heart failure. Accumulating evidence suggests that PDE9A might be a promising therapeutic target for heart diseases. The present study sought to investigate the effects and underlying mechanisms of C33(S), a novel

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service